Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) Stock Holdings Lifted by The Manufacturers Life Insurance Company

The Manufacturers Life Insurance Company lifted its holdings in shares of Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) by 14.2% in the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 34,886 shares of the company’s stock after buying an additional 4,339 shares during the period. The Manufacturers Life Insurance Company’s holdings in Atea Pharmaceuticals were worth $115,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Tidal Investments LLC bought a new position in shares of Atea Pharmaceuticals during the first quarter valued at approximately $87,000. Mirae Asset Global Investments Co. Ltd. bought a new position in Atea Pharmaceuticals during the 1st quarter worth $123,000. Public Employees Retirement System of Ohio grew its stake in Atea Pharmaceuticals by 238.8% during the 1st quarter. Public Employees Retirement System of Ohio now owns 61,033 shares of the company’s stock worth $247,000 after buying an additional 43,021 shares during the last quarter. Price T Rowe Associates Inc. MD increased its position in Atea Pharmaceuticals by 21.7% in the first quarter. Price T Rowe Associates Inc. MD now owns 67,137 shares of the company’s stock worth $272,000 after buying an additional 11,968 shares during the period. Finally, American Century Companies Inc. lifted its stake in Atea Pharmaceuticals by 14.6% in the second quarter. American Century Companies Inc. now owns 125,169 shares of the company’s stock valued at $414,000 after buying an additional 15,911 shares during the last quarter. Institutional investors and hedge funds own 86.67% of the company’s stock.

Insider Buying and Selling at Atea Pharmaceuticals

In other news, CEO Jean-Pierre Sommadossi sold 33,941 shares of the company’s stock in a transaction that occurred on Tuesday, September 17th. The shares were sold at an average price of $4.05, for a total value of $137,461.05. Following the completion of the sale, the chief executive officer now directly owns 5,890,053 shares of the company’s stock, valued at approximately $23,854,714.65. This represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. 17.80% of the stock is owned by corporate insiders.

Atea Pharmaceuticals Price Performance

AVIR opened at $3.82 on Monday. The stock’s 50 day moving average price is $3.64 and its 200 day moving average price is $3.65. The stock has a market cap of $321.73 million, a P/E ratio of -1.95 and a beta of 0.17. Atea Pharmaceuticals, Inc. has a 12 month low of $2.77 and a 12 month high of $4.60.

Atea Pharmaceuticals (NASDAQ:AVIR) last issued its quarterly earnings results on Wednesday, August 7th. The company reported ($0.48) EPS for the quarter, beating analysts’ consensus estimates of ($0.76) by $0.28. During the same period last year, the business earned ($0.34) EPS. Equities analysts anticipate that Atea Pharmaceuticals, Inc. will post -2.21 EPS for the current year.

Analyst Ratings Changes

Several research firms have recently commented on AVIR. William Blair upgraded shares of Atea Pharmaceuticals to a “strong-buy” rating in a research report on Friday, August 30th. Morgan Stanley upgraded shares of Atea Pharmaceuticals from an “underweight” rating to an “equal weight” rating and upped their target price for the stock from $2.00 to $6.88 in a research report on Tuesday, August 13th.

Atea Pharmaceuticals Profile

Atea Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes antiviral therapeutics for patients with viral infections. Its lead product candidate is AT-527, an oral antiviral candidate that is in Phase 3 SUNRISE-3 clinical trial for the treatment of patients with COVID-19.